Nattokinase is a natural enzyme produced during the fermentation of soybeans into natto, a traditional Japanese food consumed for approximately 1,000 years. Discovered in 1980, nattokinase has been investigated for its effects on blood clotting, cardiovascular health, inflammation, blood pressure, and brain function. Blood Clots and Circulation Nattokinase breaks down fibrin, a protein involved in blood clot formation. Research also describes its ability to inhibit PAI-1, support tissue plasminogen activator (tPA), and reduce platelet aggregation. Human studies have reported changes in clotting-related markers, including fibrinogen, factor VII, and factor VIII. Arterial Plaque and Cholesterol A study involving 1,062 patients reported a 36% reduction in carotid plaque size and a 21.7% reduction in artery wall thickness among participants evaluated with carotid imaging after 12 months of nattokinase supplementation, primarily at 10,800 fibrinolytic units (FU) daily. A separate randomized study comparing 6,000 FU of nattokinase with simvastatin reported plaque reductions of 36.6% and 11.5%, respectively. Simvastatin produced greater reductions in LDL cholesterol. However, a three-year placebo-controlled trial using 2,000 FU daily found no significant improvement in arterial measurements. The larger positive study was retrospective rather than randomized. Blood Pressure A 2023 meta-analysis involving 546 participants across six randomized trials reported average blood pressure reductions of 3.45 mmHg systolic and 2.32 mmHg diastolic compared with placebo. Brain Health Laboratory and animal studies have investigated nattokinase for its ability to break down amyloid proteins, reduce neuroinflammation, and influence recovery following experimental stroke. A 2026 randomized trial involving 120 patients found no significant improvement in overall cognitive scores, although an exploratory analysis reported improvements in visuospatial function. SARS-CoV-2 Spike Protein